{"product_id":"nicotinell-1-mg-mint-tablet-special-offer-2-boxes-1-box-free","title":"Nicotinell 1 mg mint tablet - Special Offer: 2 Boxes + 1 Box FREE","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0604\/4047\/7868\/files\/ChatGPT_Image_Oct_1_2026_03_46_40_PM.png?v=1790884019\" alt=\"\" width=\"413\" height=\"275\" style=\"display: block; margin-left: auto; margin-right: auto;\"\u003e\u003c\/p\u003e\n\u003ch3 data-pm-slice=\"1 1 []\"\u003e⭐ SPECIAL OFFER\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eBuy 2 Boxes of Nicotinell Mint 1 mg 204 Tablets lozenges and receive 1 FREE Box of Nicotinell Mint 1 mg 96 Tablets lozenges.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImportant:\u003c\/strong\u003e The special offer applies only when the \u003cstrong\u003eSpecial Offer\u003c\/strong\u003e package option is selected.\u003c\/p\u003e\n\u003cp\u003eThe individual \u003cstrong\u003e90 capsule and 30 capsule options are sold separately and do not include the free box.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNicotinell Mint 1 mg Lozenges Overview\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNicotinell Mint 1 mg is a lozenge that contains nicotine, a substance found in tobacco. This product is used to help people quit smoking by reducing withdrawal symptoms. It does not contain sugar.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat's in it?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMain Ingredient: 1 mg of nicotine in the form of nicotine bitartrate dihydrate (3.072 mg)\u003c\/li\u003e\n\u003cli\u003eOther Ingredients: maltitol (E 965), anhydrous sodium carbonate, sodium bicarbonate, 30% polyacrylate dispersion, xanthan gum, anhydrous colloidal silica, levomenthol, peppermint oil, aspartame (E 951), and magnesium stearate.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWho Can Use It?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis product is intended for adults (18+) who are mildly to moderately dependent on nicotine. It is not recommended for heavily dependent smokers. If you're under 18, you should seek medical advice before using.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eHow to Use It?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePlace a lozenge in your mouth and suck on it. Once the taste gets strong, move it between your cheek and gum until the taste fades, then start sucking again. Repeat until the lozenge is completely dissolved, which should take around 30 minutes. Use 1 lozenge every 1-2 hours or whenever you feel the urge to smoke. The usual dose is 8 to 12 lozenges per day, with a maximum of 30.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDosage Based on Smoking Habits:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIf you smoke fewer than 20 cigarettes a day, the 1 mg lozenge is recommended.\u003c\/li\u003e\n\u003cli\u003eIf you smoke 20 to 30 cigarettes a day, you can use either 1 mg or 2 mg lozenges based on your needs.\u003c\/li\u003e\n\u003cli\u003eIf you smoke more than 30 cigarettes a day, it's recommended to use the 2 mg lozenges.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eTreatment Duration\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe length of treatment will vary based on your response, but it should be continued for at least 3 months. You should gradually reduce the number of lozenges used after this period and stop using them entirely once you're down to 1-2 per day. It's generally not recommended to continue treatment for longer than 6 months.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWarning\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOverdose can cause a variety of symptoms, ranging from sweating and throat irritation to nausea, vomiting, diarrhea, and heart problems. In children, even small amounts can cause severe symptoms or death. If you suspect an overdose, contact a healthcare professional immediately.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWho Shouldn't Use It?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePeople who don't smoke or are allergic to nicotine or any of the other ingredients should not use this product. Also, seek medical advice before using it if you have certain medical conditions or are taking certain medications.\u003c\/p\u003e\n\u003cp\u003eAvoid coffee, acidic, and carbonated drinks 15 minutes before taking a lozenge as it can reduce the absorption of nicotine.\u003c\/p\u003e\n\u003cp\u003eNicotinell Mint 1mg is not recommended for use during pregnancy and breastfeeding without medical consultation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdditional Information\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe lozenges contain sweeteners such as aspartame and maltitol, a source of fructose, and each lozenge contains 9.8 mg of sodium. These factors should be considered if you're diabetic or on a low-salt diet.\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"color: #ff2a00;\"\u003e\u003cstrong\u003ePlease read the following full disclosure:\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eSUMMARY OF PRODUCT CHARACTERISTICS\u003c\/p\u003e\n\u003cp\u003eANSM - Updated on: 16\/07\/2020\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eNAME OF THE MEDICINE\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eNICOTINELL MINT 1 mg, lozenge\u003c\/p\u003e\n\u003col start=\"2\"\u003e\n\u003cli\u003eQUALITATIVE AND QUANTITATIVE COMPOSITION\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eNicotine ........................................................................................................................... 1.000 mg\u003c\/p\u003e\n\u003cp\u003eIn the form of nicotine bitartrate dihydrate ................................................................... 3.072 mg\u003c\/p\u003e\n\u003cp\u003eFor one lozenge.\u003c\/p\u003e\n\u003cp\u003eExcipient(s) with known effect: aspartame (0.01 g) and maltitol (0.9 g).\u003c\/p\u003e\n\u003cp\u003eFor the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003col start=\"3\"\u003e\n\u003cli\u003ePHARMACEUTICAL FORM\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eLozenge.\u003c\/p\u003e\n\u003cp\u003eWhite lozenge, mint-flavored, round and biconvex.\u003c\/p\u003e\n\u003col start=\"4\"\u003e\n\u003cli\u003eCLINICAL DATA\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e4.1. Therapeutic Indications\u003c\/p\u003e\n\u003cp\u003eTreatment of tobacco dependence in order to alleviate the symptoms of nicotine withdrawal, including craving (see section 5.1), with the aim of facilitating complete cessation of tobacco use or temporarily reducing its consumption in smokers motivated to quit.\u003c\/p\u003e\n\u003cp\u003eComplete cessation of tobacco use is the ultimate goal. Appropriate support increases the chances of success in quitting smoking.\u003c\/p\u003e\n\u003cp\u003e4.2. Dosage and Method of Administration.\u003c\/p\u003e\n\u003cdiv class=\"group w-full text-gray-800 dark:text-gray-100 border-b border-black\/10 dark:border-gray-900\/50 bg-gray-50 dark:bg-[#444654]\"\u003e\n\u003cdiv class=\"flex p-4 gap-4 text-base md:gap-6 md:max-w-2xl lg:max-w-[38rem] xl:max-w-3xl md:py-6 lg:px-0 m-auto\"\u003e\n\u003cdiv class=\"relative flex w-[calc(100%-50px)] flex-col gap-1 md:gap-3 lg:w-[calc(100%-115px)]\"\u003e\n\u003cdiv class=\"flex flex-grow flex-col gap-3\"\u003e\n\u003cdiv class=\"min-h-[20px] flex flex-col items-start gap-4 whitespace-pre-wrap break-words\"\u003e\n\u003cdiv class=\"markdown prose w-full break-words dark:prose-invert light\"\u003e\n\u003cp\u003eNICOTINELL MINT 1 mg, lozenge can be used alone (a) or in combination with NICOTINELL TTS, transdermal patch (b).\u003c\/p\u003e\n\u003cp\u003eDosage\u003c\/p\u003e\n\u003cp\u003eAdults and elderly:\u003c\/p\u003e\n\u003cp\u003ea) Treatment with NICOTINELL MINT 1 mg, lozenge only\u003c\/p\u003e\n\u003cp\u003ePatients must completely stop smoking during treatment with this medicine.\u003c\/p\u003e\n\u003cp\u003eNICOTINELL MINT 1 mg, lozenge is recommended for smokers with low to moderate nicotine dependence. It is not recommended for highly or very highly nicotine dependent smokers.\u003c\/p\u003e\n\u003cp\u003eThe initial dosage will be personalized based on the individual's nicotine dependence. The optimal dosage is described in the table below:\u003c\/p\u003e\n\u003cp\u003eLow to moderate nicotine dependence\u003c\/p\u003e\n\u003cp\u003eModerate to high nicotine dependence\u003c\/p\u003e\n\u003cp\u003eHigh to very high nicotine dependence\u003c\/p\u003e\n\u003cp\u003eLow dosage accepted\u003c\/p\u003e\n\u003cp\u003eLow dosage accepted\u003c\/p\u003e\n\u003cp\u003eHigh dosage accepted\u003c\/p\u003e\n\u003cp\u003eHigh dosage accepted\u003c\/p\u003e\n\u003cp\u003eSmoker \u0026lt; 20 cigarettes \/ day.\u003c\/p\u003e\n\u003cp\u003eSmoker of 20 to 30 cigarettes \/ day.\u003c\/p\u003e\n\u003cp\u003eSmoker \u0026gt; 30 cigarettes \/ day.\u003c\/p\u003e\n\u003cp\u003eThe use of 1 mg lozenges is recommended.\u003c\/p\u003e\n\u003cp\u003eDepending on the characteristics of the smoker, the 1 mg and 2 mg lozenges can be used.\u003c\/p\u003e\n\u003cp\u003eThe use of 2 mg lozenges is recommended.\u003c\/p\u003e\n\u003cp\u003eIn case of occurrence of adverse effects observed with the use of 2 mg tablets, use the 1 mg tablets.\u003c\/p\u003e\n\u003cp\u003eThe initial dose is one tablet every 1 to 2 hours. Suck on a tablet each time the need to smoke is felt.\u003c\/p\u003e\n\u003cp\u003eThe usual consumption is 8 to 12 tablets per day. For quitting smoking as well as for reduction, the maximum daily dose is 24 tablets. Do not use more than one tablet per hour.\u003c\/p\u003e\n\u003cp\u003eNICOTINELL tablets should be used as a priority for quitting smoking.\u003c\/p\u003e\n\u003cp\u003eComplete cessation of tobacco\u003c\/p\u003e\n\u003cp\u003ePatients must stop smoking completely during treatment with NICOTINELL tablets.\u003c\/p\u003e\n\u003cp\u003eThe duration of treatment is individual. Normally, this treatment should last at least 3 months. After 3 months, the individual gradually reduces the number of tablets. The treatment is stopped when consumption is reduced to 1 or 2 tablets per day. It is generally recommended not to use lozenges beyond 6 months. However, some ex-smokers may need longer treatment to avoid relapses.\u003c\/p\u003e\n\u003cp\u003ePatients who have used a nicotine substitute for more than 9 months are advised to seek advice from a healthcare professional.\u003c\/p\u003e\n\u003cp\u003eThe advice of a healthcare professional can help smokers quit smoking.\u003c\/p\u003e\n\u003cp\u003eReduction of tobacco consumption\u003c\/p\u003e\n\u003cp\u003eNICOTINELL tablets should be used between periods when the individual smokes, with the aim of prolonging smoke-free periods, and with the intention of reducing cigarette consumption as much as possible. The number of cigarettes should be gradually replaced by NICOTINELL tablets.\u003c\/p\u003e\n\u003cp\u003eIf a reduction in daily cigarette consumption of at least 50% has not been achieved after 6 weeks of treatment, it is recommended to seek advice from a healthcare professional.\u003c\/p\u003e\n\u003cp\u003eAn attempt to quit should be considered as soon as the smoker feels ready, but no more than 4 months after initiating treatment. After this period, the number of tablets should be gradually reduced, for example by stopping one tablet every 2-5 days. If after 6 months from the start of treatment, the attempt to completely quit smoking has failed, it is recommended to seek advice from a healthcare professional. Regular use of NICOTINELL tablets after 6 months is generally not recommended. Some ex-smokers may need longer treatment to avoid returning to tobacco consumption.\u003c\/p\u003e\n\u003cp\u003eThe advice of a healthcare professional can help smokers quit smoking.\u003c\/p\u003e\n\u003cp\u003eb) Treatment with NICOTINELL 1 mg, lozenge in combination with NICOTINELL TTS, transdermal patch.\u003c\/p\u003e\n\u003cp\u003eComplete cessation of tobacco\u003c\/p\u003e\n\u003cp\u003ePeople who have failed after being treated with NICOTINELL 1 mg, lozenge alone, can combine it with NICOTINELL TTS, transdermal patch.\u003c\/p\u003e\n\u003cp\u003eIt is advisable to stop smoking completely during treatment with NICOTINELL 1 mg, lozenge in combination with NICOTINELL TTS, transdermal patch.\u003c\/p\u003e\n\u003cp\u003eThe use of NICOTINELL TTS, transdermal patch in combination with NICOTINELL 1 mg, lozenge is recommended for smokers moderately to highly dependent on nicotine (more than 20 cigarettes per day). It is highly recommended to use this medication combination with the advice and support of a healthcare professional.\u003c\/p\u003e\n\u003cp\u003eThe maximum total treatment duration is 9 months (for the initial treatment and the reduction of the nicotine dose)\u003c\/p\u003e\n\u003cp\u003eInitial combined treatment:\u003c\/p\u003e\n\u003cp\u003eIt is advisable to start treatment with a 21 mg \/ 24 hour patch in combination with NICOTINELL 1 mg, lozenge. At least 4 tablets (1 mg) per day must be used. In most cases, 5 to 6 tablets are sufficient. Do not take more than 15 tablets per day. Normally, the treatment should last 6 to 12 weeks. Subsequently, the nicotine dose must be gradually reduced.\u003c\/p\u003e\n\u003cp\u003eThe patch is applied to a clean, dry, undamaged area where hair is rare on the trunk, upper arm, or hips. The patch should be pressed onto the skin for 10 to 20 seconds.\u003c\/p\u003e\n\u003cp\u003eTo minimize the risk of local irritation, it is advisable to apply NICOTINELL TTS, transdermal patch to a different application site than the previous one.\u003c\/p\u003e\n\u003cp\u003eIt is advisable to wash hands rigorously after handling the transdermal devices to avoid eye irritation from the nicotine deposited on the fingers.\u003c\/p\u003e\n\u003cp\u003eReduction of the nicotine dose:\u003c\/p\u003e\n\u003cp\u003eThis can be done in 2 ways.\u003c\/p\u003e\n\u003cp\u003eOption 1: Use of patches at a lower dose, that is to say: NICOTINELL TTS 14 mg \/ 24 hours, transdermal device for 3 to 6 weeks followed by NICOTINELL TTS 7 mg \/ 24 hours, transdermal device for another 3 to 6 weeks with the initial dose of NICOTINELL 1 mg, lozenge. Subsequently, the number of tablets should be gradually reduced. It is generally not recommended to use NICOTINELL 1 mg, lozenge for more than 6 months. However, some ex-smokers may need treatment for longer in order to avoid relapse of smoking but this should not exceed more than 9 months.\u003c\/p\u003e\n\u003cp\u003eOption 2: Discontinuous use of patches and gradual reduction in the number of 1 mg tablets. It is generally not recommended to use NICOTINELL 1 mg, lozenge for more than 6 months. However, some ex-smokers may need treatment for longer to avoid relapse of smoking but should not exceed more than 9 months.\u003c\/p\u003e\n\u003cp\u003ePediatric population\u003c\/p\u003e\n\u003cp\u003eNICOTINELL MINT 1 mg, lozenge should not be administered in adolescents (12-17 years) without the advice of a healthcare professional. There are no data regarding the administration of this medicine in adolescents under 18 years of age.\u003c\/p\u003e\n\u003cp\u003eNICOTINELL MINT 1 mg, lozenge should not be administered in children under 18 years old.\u003c\/p\u003e\n\u003cp\u003eRenal and hepatic insufficiency\u003c\/p\u003e\n\u003cp\u003eThis medication should be used with caution in patients with moderate to severe renal insufficiency and\/or moderate to severe hepatic insufficiency, as the clearance of nicotine or its metabolites may be decreased with the possibility of increased side effects.\u003c\/p\u003e\n\u003cp\u003eUsage tips:\u003c\/p\u003e\n\u003cp\u003e· Suck the tablet until the taste becomes strong.\u003c\/p\u003e\n\u003cp\u003e· Then place the tablet between the gum and the cheek.\u003c\/p\u003e\n\u003cp\u003e· Start sucking the tablet again when the taste has faded.\u003c\/p\u003e\n\u003cp\u003e· This process will be adapted individually and should be repeated until the tablet is completely dissolved (about 30 minutes).\u003c\/p\u003e\n\u003cp\u003eThe intake of acidic drinks such as coffee or soda can decrease the absorption of nicotine through the oral mucosa. These drinks should be avoided in the 15 minutes before taking the lozenge. Do not eat or drink with the lozenge in the mouth.\u003c\/p\u003e\n\u003cp\u003e4.3. Contraindications\u003c\/p\u003e\n\u003cp\u003e· Hypersensitivity to nicotine or to any of the excipients mentioned in section 6.1.\u003c\/p\u003e\n\u003cp\u003e· Non-smokers.\u003c\/p\u003e\n\u003cp\u003e4.4. Special warnings and precautions for use\u003c\/p\u003e\n\u003cp\u003eCardiovascular diseases: in case of recent myocardial infarction, unstable or worsening angina (including Prinzmetal angina), severe cardiac rhythm disorder, unstable arterial hypertension, or recent cerebrovascular accident, it is always recommended first to completely stop smoking without nicotine replacement therapy.\u003c\/p\u003e\n\u003cp\u003eIn case of failure in these smokers, the use of NICOTINELL MINT lozenges should be considered; however, as clinical safety data in these patients are limited, initiation of treatment should only be under medical supervision. If there is a clinically significant increase in cardiovascular or other effects attributable to nicotine, the dose of nicotine should be reduced or the medication discontinued.\u003c\/p\u003e\n\u003cp\u003eUse NICOTINELL MINT lozenges with caution in patients with hypertension, stable angina, cerebrovascular disorder, occlusive peripheral arterial diseases, heart failure, hyperthyroidism, or pheochromocytoma.\u003c\/p\u003e\n\u003cp\u003eDiabetes mellitus: Blood glucose can be more variable when quitting smoking, with or without nicotine replacement therapy. Therefore, it is important for diabetics to closely monitor their blood glucose when using this product.\u003c\/p\u003e\n\u003cp\u003eRenal or hepatic insufficiency: moderate to severe hepatic insufficiency and\/or severe renal insufficiency.\u003c\/p\u003e\n\u003cp\u003eSeizures: The potential risks and benefits of nicotine should be carefully evaluated before use in subjects taking anticonvulsant therapy or with a history of epilepsy as cases of seizures have been reported in association with nicotine.\u003c\/p\u003e\n\u003cp\u003eIn these patients, complete cessation of smoking without nicotine replacement therapy should first be recommended.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal diseases: swallowed nicotine can exacerbate symptoms in subjects suffering from esophagitis, oral or pharyngeal inflammation, gastritis, or gastric or peptic ulcer.\u003c\/p\u003e\n\u003cp\u003eKeep out of sight and reach of children.\u003c\/p\u003e\n\u003cp\u003eDanger in young children: doses of nicotine tolerated in adult smokers can cause serious, even fatal, intoxication in young children (see section 4.9).\u003c\/p\u003e\n\u003cp\u003eSpecific warnings related to excipients:\u003c\/p\u003e\n\u003cp\u003eThe NICOTINELL MINT lozenge contains aspartame, maltitol, and sodium.\u003c\/p\u003e\n\u003cp\u003eEach NICOTINELL MINT 1 mg lozenge contains 10mg of aspartame (E951), a source of phenylalanine equivalent to 5 mg\/dose; this can be dangerous\u003c\/p\u003e\n\u003cp\u003e4.5. Interactions with other medicinal products and other forms of interaction\u003c\/p\u003e\n\u003cp\u003eDrug interactions: there are no data on possible interactions between nicotine-containing lozenges and other medications.\u003c\/p\u003e\n\u003cp\u003eOther reported effects of smoking include a reduction in the analgesic effect of propoxyphene, a decrease in the diuretic effect of furosemide, a decrease in the pharmacological effect of propranolol on blood pressure and heart rate, and a decrease in the anti-ulcer effect of H2 antagonists.\u003c\/p\u003e\n\u003cp\u003eTobacco and nicotine can lead to an increase in blood concentrations of cortisol and catecholamines, such as a decrease in the effect of nifedipine or adrenergic antagonists and an increase in the effect of adrenergic agonists.\u003c\/p\u003e\n\u003cp\u003eThe increase in subcutaneous absorption of insulin that occurs when stopping smoking may require a decrease in the dose of insulin.\u003c\/p\u003e\n\u003cp\u003eRegarding interactions with other medicinal products and other forms of interaction for NICOTINELL TTS, transdermal device, see the Summary of Product Characteristics for this specialty.\u003c\/p\u003e\n\u003cp\u003e4.6. Fertility, pregnancy and lactation\u003c\/p\u003e\n\u003cp\u003ePregnancy\u003c\/p\u003e\n\u003cp\u003eSmoking during pregnancy is associated with risks such as intrauterine growth retardation, premature delivery, or stillbirth. Quitting smoking is the most effective intervention to improve the health of the pregnant woman and her baby. The earlier smoking is stopped, the better. Nicotine is transmitted to the fetus and affects its respiratory movements as well as its circulation. The effect on circulation is dose-dependent.\u003c\/p\u003e\n\u003cp\u003ePregnant women should first be advised to stop smoking without the aid of nicotine replacement therapy. If unsuccessful, the use of a nicotine substitute should only be considered after the advice of a healthcare professional.\u003c\/p\u003e\n\u003cp\u003eBreastfeeding\u003c\/p\u003e\n\u003cdiv class=\"group w-full text-gray-800 dark:text-gray-100 border-b border-black\/10 dark:border-gray-900\/50 bg-gray-50 dark:bg-[#444654]\"\u003e\n\u003cdiv class=\"flex p-4 gap-4 text-base md:gap-6 md:max-w-2xl lg:max-w-[38rem] xl:max-w-3xl md:py-6 lg:px-0 m-auto\"\u003e\n\u003cdiv class=\"relative flex w-[calc(100%-50px)] flex-col gap-1 md:gap-3 lg:w-[calc(100%-115px)]\"\u003e\n\u003cdiv class=\"flex flex-grow flex-col gap-3\"\u003e\n\u003cdiv class=\"min-h-[20px] flex flex-col items-start gap-4 whitespace-pre-wrap break-words\"\u003e\n\u003cdiv class=\"markdown prose w-full break-words dark:prose-invert light\"\u003e\n\u003cp\u003eNicotine passes into breast milk in amounts that could affect the child, including at therapeutic doses.\u003c\/p\u003e\n\u003cp\u003eTherefore, both NICOTINELL MENTHE 1 mg lozenge and smoking should be avoided during breastfeeding.\u003c\/p\u003e\n\u003cp\u003eIf quitting smoking is not fully assured, the use of the lozenge during breastfeeding should only be decided after the advice of a healthcare professional.\u003c\/p\u003e\n\u003cp\u003eIn case of use of this medication during breastfeeding, suck the NICOTINELL MENTHE 1 mg lozenge just after breastfeeding and do not take it during the two hours before the next breastfeeding.\u003c\/p\u003e\n\u003cp\u003eFertility\u003c\/p\u003e\n\u003cp\u003eSmoking increases the risk of infertility in both women and men. Both in humans and in animals, it has been demonstrated that nicotine can impair sperm quality. In animals, reduced fertility has been demonstrated.\u003c\/p\u003e\n\u003cp\u003e4.7. Effects on ability to drive and use machines\u003c\/p\u003e\n\u003cp\u003eThere is no evidence of risk regarding driving vehicles or operating machinery when treated with the recommended doses of lozenges. However, the fact that quitting smoking can cause behavioral changes should be considered.\u003c\/p\u003e\n\u003cp\u003e4.8. Side effects\u003c\/p\u003e\n\u003cp\u003eThe nicotine from the lozenges can cause side effects similar to those of nicotine absorbed through smoking, due to the pharmacological effects of nicotine, which are dose-dependent. Non-dose dependent side effects are: hypersensitivity, Quincke's edema and anaphylactic shocks.\u003c\/p\u003e\n\u003cp\u003eMost of the reported side effects occur during the first 3 or 4 weeks of treatment.\u003c\/p\u003e\n\u003cp\u003eThe nicotine from the lozenges can sometimes cause a slight irritation of the throat and increased salivation at the beginning of treatment. Swallowing too much nicotine can cause hiccups. Sensitive subjects may present mild signs of dyspepsia or gastric burns at the beginning. These symptoms can be reduced by sucking the lozenge more slowly. Excessive consumption of lozenges by subjects who did not inhale tobacco smoke can cause nausea, dizziness, and headaches.\u003c\/p\u003e\n\u003cp\u003eThe occurrence of aphthous ulceration may be more frequent when quitting smoking.\u003c\/p\u003e\n\u003cp\u003eThe following side effects detailed in Table 1 relate to all oral forms of nicotine.\u003c\/p\u003e\n\u003cp\u003eSide effects are listed below, by organ type and in order of frequency. Frequencies are defined as follows: very common (≥ 1\/10), common (≥ 1\/100 to \u0026lt; 1\/10), uncommon (≥ 1\/1000 to \u0026lt; 1\/100), rare (≥ 1\/10000 to \u0026lt; 1\/1000), very rare (\u0026lt; 1\/10000).\u003c\/p\u003e\n\u003cp\u003eSome symptoms such as dizziness, headaches, insomnia may be related to tobacco withdrawal and may be due to the administration of an insufficient dose of nicotine.\u003c\/p\u003e\n\u003cp\u003eCold sores may occur when quitting smoking, but their relationship with nicotine treatment is not established.\u003c\/p\u003e\n\u003cp\u003eThe patient may remain dependent on nicotine after quitting smoking.\u003c\/p\u003e\n\u003cp\u003eRegarding the side effects for NICOTINELL TTS transdermal device, see the Summary of Characteristics of this specialty.\u003c\/p\u003e\n\u003cp\u003eDeclaration of suspected adverse effects\u003c\/p\u003e\n\u003cp\u003eThe declaration of suspected adverse effects after authorization of the drug is important. It allows continuous monitoring of the benefit\/risk ratio of the drug. Healthcare professionals report any suspected adverse effect through the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centers - Website: \u003ca href=\"http:\/\/www.signalement-sante.gouv.fr\/\"\u003ewww.signalement-sante.gouv.fr\u003c\/a\u003e.\u003c\/p\u003e\n\u003cp\u003e4.9. Overdose\u003c\/p\u003e\n\u003cp\u003eIn case of overdose, symptoms corresponding to heavy tobacco consumption may be observed.\u003c\/p\u003e\n\u003cp\u003eEven low doses of nicotine are toxic in children and can cause symptoms of poisoning that can be fatal. If poisoning is suspected in a child, consult a doctor immediately.\u003c\/p\u003e\n\u003cp\u003eAn overdose with NICOTINELL MENTHE 1 mg lozenges can only occur if several lozenges are sucked at the same time. Generally, the toxicity of nicotine after ingestion is minimized by the early onset of nausea and vomiting following excessive nicotine exposure.\u003c\/p\u003e\n\u003cp\u003eThe signs and symptoms of an overdose should be the same as those of acute nicotine poisoning, including: general weakness, sweats, pallor, hyperhidrosis, hypersalivation, sore throat, nausea, vomiting, diarrhea, abdominal pain, hearing and visual disturbances (sensory disturbances), headache, tachycardia and cardiac arrhythmia, dyspnea, dizziness, tremors, confused state and asthenia. Prostration, hypotension, cardiovascular collapse, coma, respiratory failure and terminal seizures may occur in case of significant overdose.\u003c\/p\u003e\n\u003cp\u003eCourse of action in case of overdose:\u003c\/p\u003e\n\u003cp\u003eIn case of overdose (for example, too many tablets ingested), immediate medical assistance is required. Any nicotine intake must immediately cease, and the patient should be treated symptomatically and vital signs monitored.\u003c\/p\u003e\n\u003cp\u003eFurther management will be clinically indicated or as recommended by the national poison control center.\u003c\/p\u003e\n\u003col start=\"5\"\u003e\n\u003cli\u003ePHARMACOLOGICAL PROPERTIES\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e5.1. Pharmacodynamic properties\u003c\/p\u003e\n\u003cp\u003ePharmacotherapeutic class: DRUG USED IN NICOTINE DEPENDENCE, ATC code: N07BA01.\u003c\/p\u003e\n\u003cp\u003eMechanism of action\u003c\/p\u003e\n\u003cp\u003eNicotine, the main alkaloid of tobacco-derived products, a natural substance acting on the autonomic nervous system, is an agonist of the nicotinic receptors of the central and peripheral nervous systems that has pronounced effects on the central nervous system and the cardiovascular system. Consumed via tobacco, nicotine creates a dependency resulting in a sensation of lack and other deprivation symptoms at the cessation of administration.\u003c\/p\u003e\n\u003cp\u003eThese withdrawal symptoms include a strong urge to smoke, dysphoria, insomnia, irritability, frustration or anger, anxiety, difficulty concentrating, restlessness, and increased appetite or weight gain. The lozenges replace some of the nicotine that would have been administered by tobacco and reduce the intensity of withdrawal symptoms and the strong urge to smoke.\u003c\/p\u003e\n\u003cp\u003e5.2. Pharmacokinetic properties\u003c\/p\u003e\n\u003cp\u003eAbsorption\u003c\/p\u003e\n\u003cp\u003eThe amount of nicotine absorbed depends on the amount released and absorbed through the oral mucosa.\u003c\/p\u003e\n\u003cp\u003eMost of the nicotine from NICOTINELL MENTHE 1 mg, lozenge is absorbed through the oral mucosa.\u003c\/p\u003e\n\u003cp\u003eDue to the swallowing of saliva containing nicotine, a certain proportion of it reaches the stomach and intestine where it is inactivated. Due to the first pass hepatic effect, the systemic bioavailability of nicotine is low.\u003c\/p\u003e\n\u003cp\u003eTherefore, a high and rapid systemic concentration such as it is obtained by smoking, is rarely obtained during treatment with NICOTINELL MENTHE 1 mg, lozenge.\u003c\/p\u003e\n\u003cp\u003eThe maximum plasma concentration after single administration of NICOTINELL MENTHE 1 mg, lozenge is about 4 ng per ml; after repeated administration, this concentration is close to 10.6 ng per ml (the average nicotine level after a cigarette is 15-30 ng per ml). The plasma peak is reached about 45 minutes after a single dose and after about 30 minutes in repeated administration.\u003c\/p\u003e\n\u003cp\u003eDistribution\u003c\/p\u003e\n\u003cp\u003eThe volume of distribution after intravenous administration of nicotine is approximately (2-) 3 l\/kg and the plasma half-life is two hours. Nicotine is primarily metabolized in the liver and plasma clearance is about 1.2 l\/min; nicotine is also metabolized in the kidneys and lungs.\u003c\/p\u003e\n\u003cp\u003eNicotine crosses the blood-brain barrier.\u003c\/p\u003e\n\u003cp\u003eMetabolism\u003c\/p\u003e\n\u003cp\u003eMore than 20 metabolites have been identified, all probably less active than nicotine. The main metabolite is cotinine which has a half-life of 15-20 hours and a plasma concentration about 10 times higher than that of nicotine. The binding to plasma proteins of nicotine is less than 5%. The modification of this binding rate by drug treatments or simultaneous diseases probably has no significant effect on the kinetics of nicotine. The main urinary metabolites are cotinine (15% of the dose) and trans-3-hydroxy-cotinine (45% of the dose).\u003c\/p\u003e\n\u003cp\u003eElimination\u003c\/p\u003e\n\u003cp\u003eApproximately 10% of the nicotine is excreted unchanged. Urinary excretion can reach 30% in case of increased diuresis or pH lower than 5.\u003c\/p\u003e\n\u003cp\u003e5.3. Preclinical safety data\u003c\/p\u003e\n\u003cp\u003eNicotine has been found to be positive in some in vitro genotoxicity tests; however, negative results have also been obtained with these same tests. Nicotine was negative in in vivo tests.\u003c\/p\u003e\n\u003cp\u003eExperiments in animals have shown that nicotine causes post-implantation loss and decreases fetal growth.\u003c\/p\u003e\n\u003cp\u003eThe results of carcinogenesis tests have not provided clear evidence of a carcinogenic effect of nicotine.\u003c\/p\u003e\n\u003col start=\"6\"\u003e\n\u003cli\u003ePHARMACEUTICAL DATA\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e6.1. List of excipients\u003c\/p\u003e\n\u003cp\u003eMaltitol (E965), anhydrous sodium carbonate, sodium bicarbonate, 30% polyacrylate dispersion, xanthan gum, anhydrous colloidal silica, levomenthol, peppermint essential oil, aspartame (E951), magnesium stearate.\u003c\/p\u003e\n\u003cp\u003e6.2. Incompatibilities\u003c\/p\u003e\n\u003cp\u003eNot applicable.\u003c\/p\u003e\n\u003cp\u003e6.3. Shelf life\u003c\/p\u003e\n\u003cp\u003e2 years\u003c\/p\u003e\n\u003cp\u003e6.4. Special precautions for storage\u003c\/p\u003e\n\u003cp\u003eStore at a temperature not exceeding + 25ºC.\u003c\/p\u003e\n\u003cp\u003e6.5. Nature and contents of outer packaging\u003c\/p\u003e\n\u003cp\u003ePolypropylene tube of 24, 72, 96 or 144 tablets with a closure cap containing a molecular sieve desiccant sleeve along the inner wall of the tube.\u003c\/p\u003e\n\u003cp\u003eBoxes of 12, 36, 72, 96, 144 or 204 tablets in opaque thermoformed blisters (Aluminium-PVC\/PE\/PVDC\/PE\/PVC).\u003c\/p\u003e\n\u003cp\u003eNot all pack sizes may be marketed.\u003c\/p\u003e\n\u003cp\u003e6.6. Special precautions for disposal and handling\u003c\/p\u003e\n\u003cp\u003eNo special requirements.\u003c\/p\u003e\n\u003col start=\"7\"\u003e\n\u003cli\u003eMARKETING AUTHORIZATION HOLDER\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eGLAXOSMITHKLINE CONSUMER HEALTHCARE\u003c\/p\u003e\n\u003cp\u003e23 RUE FRANCOIS JACOB\u003c\/p\u003e\n\u003cp\u003e92500 RUEIL MALMAISON\u003c\/p\u003e\n\u003col start=\"8\"\u003e\n\u003cli\u003eMARKETING AUTHORIZATION NUMBER(S)\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e· 34009 364 088 1 4: 12 lozenges in thermoformed blisters (Aluminium-PVC\/PE\/PVDC\/PE\/PVC).\u003c\/p\u003e\n\u003cp\u003e· 34009 364 089 8 2: 36 lozenges in thermoformed blisters (Aluminium-PVC\/PE\/PVDC\/PE\/PVC).\u003c\/p\u003e\n\u003cp\u003e· 34009 389 198 5 1: 72 lozenges in thermoformed blisters (Aluminium-PVC\/PE\/PVDC\/PE\/PVC).\u003c\/p\u003e\n\u003cp\u003e· 34009 364 090 6 4: 96 lozenges in thermoformed blisters (Aluminium-PVC\/PE\/PVDC\/PE\/PVC).\u003c\/p\u003e\n\u003cp\u003e· 34009 389 199 1 2: 144 lozenges in thermoformed blisters (Aluminium-PVC\/PE\/PVDC\/PE\/PVC).\u003c\/p\u003e\n\u003cp\u003e· 34009 364 091 2 5: 204 lozenges in thermoformed blisters (Aluminium-PVC\/PE\/PVDC\/PE\/PVC).\u003c\/p\u003e\n\u003col start=\"9\"\u003e\n\u003cli\u003eDATE OF FIRST AUTHORIZATION\/RENEWAL OF THE AUTHORIZATION\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e[to be completed later by the holder]\u003c\/p\u003e\n\u003col start=\"10\"\u003e\n\u003cli\u003eDATE OF UPDATE OF THE TEXT\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e[to be completed later by the holder]\u003c\/p\u003e\n\u003col start=\"11\"\u003e\n\u003cli\u003eDOSIMETRY\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eNot applicable.\u003c\/p\u003e\n\u003col start=\"12\"\u003e\n\u003cli\u003eINSTRUCTIONS FOR THE PREPARATION OF RADIOPHARMACEUTICALS\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eNot applicable.\u003c\/p\u003e\n\u003cp\u003ePRESCRIPTION AND DELIVERY CONDITIONS\u003c\/p\u003e\n\u003cp\u003eOver-the-counter medication.\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cstrong\u003e🎉 Special Promotional Offer\u003c\/strong\u003e\u003cbr\u003eEnjoy this product at a special promotional price. \u003cstrong\u003eStandard Shipping only — please allow 7–14 days for delivery.\u003c\/strong\u003e \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Pharmarcie.com","offers":[{"title":"Default Title","offer_id":47554572943532,"sku":"P3400936409125","price":132.74,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0604\/4047\/7868\/files\/ChatGPTImageOct1_2026_03_56_48PM.png?v=1790884718","url":"https:\/\/pharmarcie.com\/products\/nicotinell-1-mg-mint-tablet-special-offer-2-boxes-1-box-free","provider":"Pharmarcie.com","version":"1.0","type":"link"}